These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31019437)

  • 21. The impact of an 'evergreening' strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands.
    Kirshner G; Makai P; Brouns C; Timmers L; Kemp R
    Eur J Health Econ; 2024 Sep; 25(7):1147-1163. PubMed ID: 38190008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies.
    Moorkens E; Jonker-Exler C; Huys I; Declerck P; Simoens S; Vulto AG
    Front Pharmacol; 2016; 7():193. PubMed ID: 27445826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Inflation Reduction Act: A boon for the generic and biosimilar industry.
    Niazi SK
    J Clin Pharm Ther; 2022 Nov; 47(11):1738-1751. PubMed ID: 36207987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
    Lee HJ; Han E; Kim H
    Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolving role of biosimilars in haematology-oncology: a practical perspective.
    Gascon P
    Ther Adv Hematol; 2015 Dec; 6(6):267-81. PubMed ID: 26622996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Why is there no biosimilar of Erbitux®?
    Douez E; D'Atri V; Guillarme D; Antier D; Guerriaud M; Beck A; Watier H; Foucault-Fruchard L
    J Pharm Biomed Anal; 2023 Sep; 234():115544. PubMed ID: 37418870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape.
    Moorkens E; Meuwissen N; Huys I; Declerck P; Vulto AG; Simoens S
    Front Pharmacol; 2017; 8():314. PubMed ID: 28642701
    [No Abstract]   [Full Text] [Related]  

  • 28. Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching.
    Declerck P; Bakalos G; Zintzaras E; Barton B; Schreitmüller T
    Clin Ther; 2018 May; 40(5):798-809.e2. PubMed ID: 29699853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An evaluation of the utilisation of biosimilar monoclonal antibody drugs in Ireland and barriers to their usage.
    Coakley KE; Bambury RM; McGuinness E; Dennehy M; Ronayne C; Cahill M; O'Reilly S
    Ir J Med Sci; 2024 Jun; 193(3):1191-1199. PubMed ID: 38194005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilar monoclonal antibodies in China: A patent review.
    Liu JW; Yang YH; Wu N; Wei JF
    Bioengineered; 2022 Jun; 13(6):14503-14518. PubMed ID: 35758066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.
    Beck A; Reichert JM
    MAbs; 2013; 5(5):621-3. PubMed ID: 23924791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars as a Future, Promising Solution for Financial Toxicity: A Review with Emphasis on Bevacizumab.
    Saleem T; Qurashi H; Jamali M; Chan Gomez J; Kanderi T
    Cureus; 2020 Jul; 12(7):e9300. PubMed ID: 32832297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story.
    Tan SH; Goh LGH; Ong BSK; Ng DSG; Lin L; Ng RCH; Thong BY; Ng K
    Pharmacoecon Open; 2024 Sep; 8(5):679-688. PubMed ID: 39042227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab biosimilars.
    Vital EM; Kay J; Emery P
    Expert Opin Biol Ther; 2013 Jul; 13(7):1049-62. PubMed ID: 23600760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilar in Breast Cancer: A Narrative Review.
    Barman D; Bandyopadhyay T; Talukdar R
    Cureus; 2024 Jan; 16(1):e52828. PubMed ID: 38406112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis.
    Na H; Kwon SH; Son KH; Baek Y; Kim J; Lee EK
    BioDrugs; 2023 Mar; 37(2):205-218. PubMed ID: 36729329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Biosimilars in rheumatology and other fields of medicine].
    Milchert M; Fliciński J; Brzosko M
    Postepy Hig Med Dosw (Online); 2014 Jul; 68():970-5. PubMed ID: 25055035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A place for biosimilars in the changing multiple sclerosis treatment landscape.
    Greenberg B; Giovannoni G
    Mult Scler Relat Disord; 2023 Sep; 77():104841. PubMed ID: 37467536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Clinical Review of Biosimilars Approved in Oncology.
    Ngo D; Chen J
    Ann Pharmacother; 2021 Mar; 55(3):362-377. PubMed ID: 32715722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilars in Belgium: a proposal for a more competitive market.
    Moorkens E; Vulto AG; Huys I
    Acta Clin Belg; 2021 Dec; 76(6):441-452. PubMed ID: 32400319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.